Uploaded November 2026 | Updated November 2026, 14 hours ago
Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive 84-week results from the phase 3 OPTIMA trial extension, evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).
View the full interview at checkrare.com/garetosmab-demonstrates-sustained-efficacy-in-adults-with-fibrodysplasia-ossificans-progressiva-fop
Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive 84-week results from the phase 3 OPTIMA trial extension, evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).
View the full interview at checkrare.com/garetosmab-demonstrates-sustained-efficacy-in-adults-with-fibrodysplasia-ossificans-progressiva-fop










